Sam Williams - Observer

Sam has 18 years' experience in the biotech industry, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and chief executive. From 2002 to 2007 he worked at Lehman Brothers where he was ranked the number one European biotechnology equity analyst by Institutional Investor magazine three years in a row, before becoming Industry Group Leader for Pharmaceuticals and Chemicals. Sam left Lehman in 2007 to establish Modern Biosciences (MBS), a London-based company development treatments for autoimmune diseases. MBS’ lead drug for rheumatoid arthritis is in Phase 1 studies and is the subject of a £176m Option and Licensing agreement with Janssen Biotech Inc (J&J) signed in November 2014. As well as being CEO of MBS, Sam oversees the biotechnology portfolio of the FTSE 250 company IP Group plc and sits on the Group’s Executive Committee. He is a board member of Diurnal Group plc, C4X Discovery Holdings Plc and the UK BioIndustry Association (BIA), and serves on the Translational Awards Advisory Committee of the British Heart Foundation (BHF). Sam has a PhD in molecular biology from Cambridge University.